Bacterium Clinical Trials Immune Response Protein 
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.
XTalks
JANUARY 20, 2021
While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 2, 2022
Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. About Pneumococcal disease.
The Pharma Data
MAY 31, 2022
Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. Phase III is expected to start in the short term.
XTalks
NOVEMBER 10, 2020
Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. Adjuvants are used to help stimulate stronger vaccine immune responses. Based on the encouraging Phase I data, Medicago says it plans to proceed with its Phase II/III trials.
pharmaphorum
JULY 14, 2021
The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.
Expert insights. Personalized for you.
75 
Let's personalize your content